183 related articles for article (PubMed ID: 24114040)
1. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
2. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
3. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis.
Ko FC; Chan LK; Sze KM; Yeung YS; Tse EY; Lu P; Yu MH; Ng IO; Yam JW
Nat Commun; 2013; 4():1618. PubMed ID: 23511482
[TBL] [Abstract][Full Text] [Related]
4. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.
Ko FC; Chan LK; Tung EK; Lowe SW; Ng IO; Yam JW
Gastroenterology; 2010 Oct; 139(4):1397-407. PubMed ID: 20600027
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application.
Ren G; Li G
Int J Biol Macromol; 2021 Jul; 182():264-275. PubMed ID: 33836193
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
7. GAP-independent functions of DLC1 in metastasis.
Barras D; Widmann C
Cancer Metastasis Rev; 2014 Mar; 33(1):87-100. PubMed ID: 24338004
[TBL] [Abstract][Full Text] [Related]
8. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling.
Scholz RP; Regner J; Theil A; Erlmann P; Holeiter G; Jähne R; Schmid S; Hausser A; Olayioye MA
J Cell Sci; 2009 Jan; 122(Pt 1):92-102. PubMed ID: 19066281
[TBL] [Abstract][Full Text] [Related]
9. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
11. Tensin1 positively regulates RhoA activity through its interaction with DLC1.
Shih YP; Sun P; Wang A; Lo SH
Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649
[TBL] [Abstract][Full Text] [Related]
12. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Yang X; Popescu NC; Zimonjic DB
Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
[TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
[TBL] [Abstract][Full Text] [Related]
14. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
15. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
16. SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions.
Tripathi BK; Anderman MF; Qian X; Zhou M; Wang D; Papageorge AG; Lowy DR
J Cell Biol; 2019 Sep; 218(9):3060-3076. PubMed ID: 31308216
[TBL] [Abstract][Full Text] [Related]
17. SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP.
Chau JE; Vish KJ; Boggon TJ; Stiegler AL
Nat Commun; 2022 Aug; 13(1):4788. PubMed ID: 35970859
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
19. Rho regulation: DLC proteins in space and time.
Braun AC; Olayioye MA
Cell Signal; 2015 Aug; 27(8):1643-51. PubMed ID: 25889896
[TBL] [Abstract][Full Text] [Related]
20. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]